Examination of prognostic factors in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis

This study investigated the prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (MDA5-DM). This study analysed 34 MDA5-DM cases (20 and 14 in the survival and death groups, respectively) encountered at Kurume University between 2008 and 2021. The c...

Full description

Saved in:
Bibliographic Details
Published in:Modern rheumatology 2024-08, Vol.34 (5), p.966-972
Main Authors: Sugi, Suzuna, Tominaga, Masaki, Kaieda, Shinjiro, Fujimoto, Kiminori, Chikasue, Tomonori, Koga, Takuma, Hasuo, Yuri, Iwanaga, Erina, Murotani, Kenta, Lim, Jamie Kristen T, Ida, Hiroaki, Kawayama, Tomotaka, Hoshino, Tomoaki
Format: Article
Language:English
Subjects:
Adult
Aged
Autoantibodies - blood
Autoantibodies - immunology
C-Reactive Protein - analysis
Dermatomyositis - blood
Dermatomyositis - diagnosis
Dermatomyositis - immunology
Female
Humans
Interferon-Induced Helicase, IFIH1 - immunology
Male
Middle Aged
Prognosis
Retrospective Studies
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study investigated the prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (MDA5-DM). This study analysed 34 MDA5-DM cases (20 and 14 in the survival and death groups, respectively) encountered at Kurume University between 2008 and 2021. The clinical, physiological, and computed tomography findings, pulmonary function, and serological results were retrospectively evaluated for each MDA5-DM case during the first visit and throughout the next 12 weeks. In the death group, the mean age of patients was higher (47.6 vs. 61.8 years), while the duration from symptom onset to consultation was shorter (110 vs. 34.9 days). During the first visit, the death group demonstrated a significantly higher serum C-reactive protein level (0.52 vs. 1.99) and a significantly lower albumin level (3.23 vs. 2.63) than the survival group; this persisted throughout the next 12 weeks. Poor prognosis was associated with C-reactive protein and albumin levels >0.19 mg/dl and
ISSN:1439-7595
1439-7609
1439-7609
DOI:10.1093/mr/roae007